Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence

Michael A Dawes, Bankole A. Johnson, Jennie Z. Ma, Nassima Ait-Daoud, Suzanne E. Thomas, Jack R. Cornelius

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Recently, we reported that ondansetron (a 5-HT3 antagonist) as an adjunct to cognitive behavioral therapy (CBT) produced significant within-group decreases (improvement) in drinking in adolescents with alcohol dependence. We previously have hypothesized that the mechanism of ondansetron treatment response in adolescents with alcohol dependence should be similar to early onset adult alcoholics, wherein blockade of serotonin-3 receptors may decrease dopamine release and subsequent alcohol consumption and craving. We now suggest that one mechanism by which ondansetron diminishes drinking in adolescents with alcohol dependence is through a reduction in "craving" as measured by the Adolescent Obsessive-Compulsive Drinking Scale (A-OCDS). We conducted an 8-week, prospective, open-label study of ondansetron (4 μg/kg b.i.d.) in 12 adolescents (age 14-20 years) who had alcohol dependence. Results showed that "irresistibility" and total scores as measured by the A-OCDS were correlated significantly with drinking indices (drinks / day, percent days abstinent) at the end of treatment, and that "irresistibility" and total A-OCDS scores decreased significantly by the end of treatment. These preliminary results suggest that the A-OCDS can be useful as an outcome measure in clinical studies of adolescents with alcohol dependence.

Original languageEnglish (US)
Pages (from-to)1630-1637
Number of pages8
JournalAddictive Behaviors
Volume30
Issue number9
DOIs
StatePublished - Oct 2005

Fingerprint

Ondansetron
Alcoholism
Drinking
Labels
Alcohols
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Cognitive Therapy
Alcoholics
Craving
Dopamine
Alcohol Drinking
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • Adolescence
  • Alcohol dependence
  • Craving
  • Obsessive-compulsive drinking
  • Ondansetron
  • Open-label trial

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. / Dawes, Michael A; Johnson, Bankole A.; Ma, Jennie Z.; Ait-Daoud, Nassima; Thomas, Suzanne E.; Cornelius, Jack R.

In: Addictive Behaviors, Vol. 30, No. 9, 10.2005, p. 1630-1637.

Research output: Contribution to journalArticle

Dawes, Michael A ; Johnson, Bankole A. ; Ma, Jennie Z. ; Ait-Daoud, Nassima ; Thomas, Suzanne E. ; Cornelius, Jack R. / Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. In: Addictive Behaviors. 2005 ; Vol. 30, No. 9. pp. 1630-1637.
@article{185f17b6886c4bbb8ed7121056c76a95,
title = "Reductions in and relations between {"}craving{"} and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence",
abstract = "Recently, we reported that ondansetron (a 5-HT3 antagonist) as an adjunct to cognitive behavioral therapy (CBT) produced significant within-group decreases (improvement) in drinking in adolescents with alcohol dependence. We previously have hypothesized that the mechanism of ondansetron treatment response in adolescents with alcohol dependence should be similar to early onset adult alcoholics, wherein blockade of serotonin-3 receptors may decrease dopamine release and subsequent alcohol consumption and craving. We now suggest that one mechanism by which ondansetron diminishes drinking in adolescents with alcohol dependence is through a reduction in {"}craving{"} as measured by the Adolescent Obsessive-Compulsive Drinking Scale (A-OCDS). We conducted an 8-week, prospective, open-label study of ondansetron (4 μg/kg b.i.d.) in 12 adolescents (age 14-20 years) who had alcohol dependence. Results showed that {"}irresistibility{"} and total scores as measured by the A-OCDS were correlated significantly with drinking indices (drinks / day, percent days abstinent) at the end of treatment, and that {"}irresistibility{"} and total A-OCDS scores decreased significantly by the end of treatment. These preliminary results suggest that the A-OCDS can be useful as an outcome measure in clinical studies of adolescents with alcohol dependence.",
keywords = "Adolescence, Alcohol dependence, Craving, Obsessive-compulsive drinking, Ondansetron, Open-label trial",
author = "Dawes, {Michael A} and Johnson, {Bankole A.} and Ma, {Jennie Z.} and Nassima Ait-Daoud and Thomas, {Suzanne E.} and Cornelius, {Jack R.}",
year = "2005",
month = "10",
doi = "10.1016/j.addbeh.2005.07.004",
language = "English (US)",
volume = "30",
pages = "1630--1637",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence

AU - Dawes, Michael A

AU - Johnson, Bankole A.

AU - Ma, Jennie Z.

AU - Ait-Daoud, Nassima

AU - Thomas, Suzanne E.

AU - Cornelius, Jack R.

PY - 2005/10

Y1 - 2005/10

N2 - Recently, we reported that ondansetron (a 5-HT3 antagonist) as an adjunct to cognitive behavioral therapy (CBT) produced significant within-group decreases (improvement) in drinking in adolescents with alcohol dependence. We previously have hypothesized that the mechanism of ondansetron treatment response in adolescents with alcohol dependence should be similar to early onset adult alcoholics, wherein blockade of serotonin-3 receptors may decrease dopamine release and subsequent alcohol consumption and craving. We now suggest that one mechanism by which ondansetron diminishes drinking in adolescents with alcohol dependence is through a reduction in "craving" as measured by the Adolescent Obsessive-Compulsive Drinking Scale (A-OCDS). We conducted an 8-week, prospective, open-label study of ondansetron (4 μg/kg b.i.d.) in 12 adolescents (age 14-20 years) who had alcohol dependence. Results showed that "irresistibility" and total scores as measured by the A-OCDS were correlated significantly with drinking indices (drinks / day, percent days abstinent) at the end of treatment, and that "irresistibility" and total A-OCDS scores decreased significantly by the end of treatment. These preliminary results suggest that the A-OCDS can be useful as an outcome measure in clinical studies of adolescents with alcohol dependence.

AB - Recently, we reported that ondansetron (a 5-HT3 antagonist) as an adjunct to cognitive behavioral therapy (CBT) produced significant within-group decreases (improvement) in drinking in adolescents with alcohol dependence. We previously have hypothesized that the mechanism of ondansetron treatment response in adolescents with alcohol dependence should be similar to early onset adult alcoholics, wherein blockade of serotonin-3 receptors may decrease dopamine release and subsequent alcohol consumption and craving. We now suggest that one mechanism by which ondansetron diminishes drinking in adolescents with alcohol dependence is through a reduction in "craving" as measured by the Adolescent Obsessive-Compulsive Drinking Scale (A-OCDS). We conducted an 8-week, prospective, open-label study of ondansetron (4 μg/kg b.i.d.) in 12 adolescents (age 14-20 years) who had alcohol dependence. Results showed that "irresistibility" and total scores as measured by the A-OCDS were correlated significantly with drinking indices (drinks / day, percent days abstinent) at the end of treatment, and that "irresistibility" and total A-OCDS scores decreased significantly by the end of treatment. These preliminary results suggest that the A-OCDS can be useful as an outcome measure in clinical studies of adolescents with alcohol dependence.

KW - Adolescence

KW - Alcohol dependence

KW - Craving

KW - Obsessive-compulsive drinking

KW - Ondansetron

KW - Open-label trial

UR - http://www.scopus.com/inward/record.url?scp=26644455703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26644455703&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2005.07.004

DO - 10.1016/j.addbeh.2005.07.004

M3 - Article

C2 - 16084024

AN - SCOPUS:26644455703

VL - 30

SP - 1630

EP - 1637

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

IS - 9

ER -